Your browser doesn't support javascript.
loading
Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection.
Sulbaran, Guidenn; Maisonnasse, Pauline; Amen, Axelle; Effantin, Gregory; Guilligay, Delphine; Dereuddre-Bosquet, Nathalie; Burger, Judith A; Poniman, Meliawati; Grobben, Marloes; Buisson, Marlyse; Dergan Dylon, Sebastian; Naninck, Thibaut; Lemaître, Julien; Gros, Wesley; Gallouët, Anne-Sophie; Marlin, Romain; Bouillier, Camille; Contreras, Vanessa; Relouzat, Francis; Fenel, Daphna; Thepaut, Michel; Bally, Isabelle; Thielens, Nicole; Fieschi, Franck; Schoehn, Guy; van der Werf, Sylvie; van Gils, Marit J; Sanders, Rogier W; Poignard, Pascal; Le Grand, Roger; Weissenhorn, Winfried.
Afiliação
  • Sulbaran G; Univ. Grenoble Alpes, CEA, CNRS, Institut de Biologie Structurale (IBS), Grenoble, France.
  • Maisonnasse P; Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses, France.
  • Amen A; Univ. Grenoble Alpes, CEA, CNRS, Institut de Biologie Structurale (IBS), Grenoble, France.
  • Effantin G; Univ. Grenoble Alpes, CEA, CNRS, Institut de Biologie Structurale (IBS), Grenoble, France.
  • Guilligay D; Univ. Grenoble Alpes, CEA, CNRS, Institut de Biologie Structurale (IBS), Grenoble, France.
  • Dereuddre-Bosquet N; Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses, France.
  • Burger JA; Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, University of Amsterdam, Location AMC, Amsterdam, the Netherlands.
  • Poniman M; Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, University of Amsterdam, Location AMC, Amsterdam, the Netherlands.
  • Grobben M; Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, University of Amsterdam, Location AMC, Amsterdam, the Netherlands.
  • Buisson M; Univ. Grenoble Alpes, CEA, CNRS, Institut de Biologie Structurale (IBS), Grenoble, France.
  • Dergan Dylon S; Univ. Grenoble Alpes, CEA, CNRS, Institut de Biologie Structurale (IBS), Grenoble, France.
  • Naninck T; Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses, France.
  • Lemaître J; Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses, France.
  • Gros W; Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses, France.
  • Gallouët AS; Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses, France.
  • Marlin R; Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses, France.
  • Bouillier C; Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses, France.
  • Contreras V; Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses, France.
  • Relouzat F; Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses, France.
  • Fenel D; Univ. Grenoble Alpes, CEA, CNRS, Institut de Biologie Structurale (IBS), Grenoble, France.
  • Thepaut M; Univ. Grenoble Alpes, CEA, CNRS, Institut de Biologie Structurale (IBS), Grenoble, France.
  • Bally I; Univ. Grenoble Alpes, CEA, CNRS, Institut de Biologie Structurale (IBS), Grenoble, France.
  • Thielens N; Univ. Grenoble Alpes, CEA, CNRS, Institut de Biologie Structurale (IBS), Grenoble, France.
  • Fieschi F; Univ. Grenoble Alpes, CEA, CNRS, Institut de Biologie Structurale (IBS), Grenoble, France.
  • Schoehn G; Univ. Grenoble Alpes, CEA, CNRS, Institut de Biologie Structurale (IBS), Grenoble, France.
  • van der Werf S; Molecular Genetics of RNA Viruses, Department of Virology, Institut Pasteur, CNRS UMR 3569, Université de Paris, Paris, France.
  • van Gils MJ; National Reference Center for Respiratory Viruses, Institut Pasteur, Paris, France.
  • Sanders RW; Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, University of Amsterdam, Location AMC, Amsterdam, the Netherlands.
  • Poignard P; Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, University of Amsterdam, Location AMC, Amsterdam, the Netherlands.
  • Le Grand R; Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY, USA.
  • Weissenhorn W; Univ. Grenoble Alpes, CEA, CNRS, Institut de Biologie Structurale (IBS), Grenoble, France.
Cell Rep Med ; 3(2): 100528, 2022 02 15.
Article em En | MEDLINE | ID: mdl-35233549
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused an ongoing global health crisis. Here, we present as a vaccine candidate synthetic SARS-CoV-2 spike (S) glycoprotein-coated lipid vesicles that resemble virus-like particles. Soluble S glycoprotein trimer stabilization by formaldehyde cross-linking introduces two major inter-protomer cross-links that keep all receptor-binding domains in the "down" conformation. Immunization of cynomolgus macaques with S coated onto lipid vesicles (S-LVs) induces high antibody titers with potent neutralizing activity against the vaccine strain, Alpha, Beta, and Gamma variants as well as T helper (Th)1 CD4+-biased T cell responses. Although anti-receptor-binding domain (RBD)-specific antibody responses are initially predominant, the third immunization boosts significant non-RBD antibody titers. Challenging vaccinated animals with SARS-CoV-2 shows a complete protection through sterilizing immunity, which correlates with the presence of nasopharyngeal anti-S immunoglobulin G (IgG) and IgA titers. Thus, the S-LV approach is an efficient and safe vaccine candidate based on a proven classical approach for further development and clinical testing.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinação / Vacinas de Partículas Semelhantes a Vírus / Glicoproteína da Espícula de Coronavírus / Vacinas contra COVID-19 / SARS-CoV-2 / COVID-19 Limite: Animals / Humans / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinação / Vacinas de Partículas Semelhantes a Vírus / Glicoproteína da Espícula de Coronavírus / Vacinas contra COVID-19 / SARS-CoV-2 / COVID-19 Limite: Animals / Humans / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article